Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc EVP & CFO Terrance P. Coyne, through entity TPC RP EPA1 LLC, reported an open-market sale of 64,399 Class A Ordinary Shares on May 26, 2026 at a weighted average price of $53.9778 per share, executed under a pre-arranged Rule 10b5-1 trading plan. After this sale, that entity held no remaining shares, while other reported direct and indirect accounts continued to hold Class A Ordinary Shares.
Royalty Pharma plc entered into a new $1.8 billion unsecured revolving credit facility with Bank of America and a syndicate of lenders. This facility replaces the company’s prior revolving credit agreement, and all obligations and commitments under the old facility were fully repaid and terminated at effectiveness.
The new Revolving Credit Facility bears interest at either a base rate tied to prime, federal funds plus 0.5%, or Term SOFR plus 1%, or at SOFR/alternative currency rates plus an applicable margin, with a commitment fee on unused amounts. It matures on May 22, 2031 and includes financial covenants requiring a consolidated leverage ratio at or below 4.00 to 1.00, a portfolio cash flow ratio at or below 5.00 to 1.00, and a coverage ratio at or above 2.50 to 1.00, with slightly higher leverage and cash flow limits following qualifying material acquisitions.
RPRX affiliates filed a Form 144 reporting proposed sales of Common Stock. The notice lists multiple awards "acquired as compensation -- Performance Awards" dated 05/08/2025, 02/11/2026, and 05/06/2026 with 13,510, 26,626, and 24,263 shares respectively. The filing also records recent completed sales by related entities on 03/02/2026, 03/23/2026, 04/01/2026, and 04/28/2026 showing per‑date executions of 1,875 and 32,916 shares by two affiliated holders.
Royalty Pharma plc EVP Marshall Urist reported an open-market sale of Class A Ordinary Shares. On May 20, 2026, he sold 13,684 shares at a weighted average price of $52.7505 per share in multiple transactions between $52.62 and $52.96.
After the sale, Urist directly owned 18,197 Class A Ordinary Shares and indirectly owned 19,020 shares through an IRA. All reported transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026, indicating a scheduled disposition rather than an opportunistic trade.
Royalty Pharma plc reported a Rule 144 notice for proposed resale of 13,684 shares of Common Stock. The filing lists a 02/11/2026 Equity Performance Award of Class A Ordinary Shares and a reported sale by Marshall Urist of 13,684 shares on 05/14/2026.
Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported an open-market sale of 13,684 Class A Ordinary Shares on May 14, 2026 at a weighted average price of $53.0647 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026.
Following the sale, Urist directly holds 31,881 Class A Ordinary Shares and indirectly holds 19,020 shares through an IRA. The sale price reflected multiple transactions within a range of $52.88 to $53.25 per share.
Royalty Pharma plc director Gregory Norden reported an open-market sale of Class A Ordinary Shares. On May 14, 2026, he sold 3,045 shares at $53.00 per share. After this transaction, he directly holds 191,803 Class A Ordinary Shares.
The filing notes the trade was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026, indicating the sale timing was scheduled in advance rather than decided opportunistically.
Royalty Pharma plc filed a Form 144 reporting the proposed sale of 3,045 shares of Common Stock on 05/13/2026. The notice lists Merrill Lynch, 225 Liberty Street, Floor 37, New York as the broker and references the vesting of restricted stock unit awards granted under the issuer equity compensation plan.
Royalty Pharma plc reported a proposed sale under Form 144 for 13,684 shares. The filing lists related equity performance awards granted on 08/06/2025 (2,772 shares), 11/05/2025 (4,626 shares) and 02/11/2026 (6,286 shares).
The cover shows an aggregate value of $726,137.82 and the filing is dated 05/14/2026.
Royalty Pharma PLC disclosure: Capital International Investors reports beneficial ownership of 37,772,419 shares, representing 8.8% of the 428,418,612 shares believed to be outstanding. The filing is an Amendment No. 3 to a Schedule 13G/A and is signed on 05/13/2026.
The filing states CII has sole power to vote on 37,448,042 shares and sole dispositive power over 37,772,419 shares. The disclosure names the investment management entities that make up Capital International Investors.